Hericium erinaceus, Lion's Mane, Monkey's Head, Houtou (infrequent), Igelstachelbart, Pom Pom Blanc, Hedgehog Mushroom, Satyr’s Beard
Currently, the only human study has used an oral dose of 1,000mg Yamabushitake (96% purity extract) thrice daily for a cumulative total of 3,000mg extract. While it is unknown if this is the optimal dose or not, it appeared to be effective.
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what effects yamabushitake has on your body, and how strong these effects are.
|Grade||Level of Evidence|
|A||Robust research conducted with repeated double-blind clinical trials|
|B||Multiple studies where at least two are double-blind and placebo controlled|
|C||Single double-blind study or multiple cohort studies|
|D||Uncontrolled or observational studies only|
Level of Evidence
||Magnitude of Effect Size
Decreases in anxiety noted, this may be secondary to menopausal symptom reduction
The rate of cognitive decline seen with oral supplementation of yamabushitake appears to be significantly reduced in older persons, although there are no direct comparisons ... show
Decrease in depressive symptoms has been noted, which may be secondary to attenuating menopausal symptoms
|C||Symptoms of Menopause||
Menopausal symptoms have been reduced, but this was mostly due to the reported antidepressant and anxiolytic properties of the mushroom.
No significant effects on sleep quality
Yamabushitake is a mushroom that grows on old or dead broadleaf trees, and is consumed in Japan and China without reported harmful effects.
Some common names for this mushroom also include Monkey's Head, Lion's Mane, and Satyr’s Beard and is sometimes called Houtou as that is the name of a sports drink which contained Hericium erinaceus (11th Asia Sport Festival in China of 1990).
The mushroom Yamabushitake (Hericium erinaceus) contains:
And a polysacchaide component (Hericium erinaceus ) - Polysaccharides, named HEF-P and belonging to the beta-glucan family; which can be broken down into four polysaccharides The percentage of polysaccharides in the fruiting bodies seems to be around 20%, with 18.59% found with an ethanol extraction with the overall structure of these polysaccharides comprising xylose (7.8%), ribose (2.7%), glucose (68.4%), arabinose (11.3%), galactose (2.5%) and mannose (5.2%).
Like most medicinal mushrooms, Yamabushitake appears to have bioactive polysaccharides (carbohydrates) in addition to some ethanolic soluble molecules
The total phenolic content of Yamabushitake appears to be in the range of 10.20+/-2.25mg gallic acid equivalents (GAE) per gram (about 1%) with the hot water extract, which appears to be up to 5-fold higher than oven cooked levels and either methanolic or freeze-dried fruit bodies. This 10.20+/-2.25mg GAE/g (phenolic content) is significantly less than the reference drug of Quercetin (194.24+/-7.58) and on a potency basis the overall antioxidant potential of yamabushitake is about 17.7% that of quercetin in vitro.
The polysaccharides themselve are also active in vivo, with 300mg/kg of the polysaccharides daily for 15 days can reduce the oxidative changes induced by ischemia/reperfusion.
The phenolic antioxidant potential of yamabushitake is significantly less than the reference drugs of Quercetin and gallic acid, although the polysaccharide content does also appear to be bioactive
Yamabushitake has been noted to increase mRNA expression of nerve-growth factor (NGF) in isolated astrocytes to around 5-fold that of control at 100-150ug/mL of the ethanolic extract in a concentration dependent manner, with no efficacy noted in the water extract. When testing hericenones C-E, none were found effective in the range of 10-100ug/mL and inhibiting JNK signalling appears to prevent yamabushitake from acting (with p38 MAPK, PKA, PKC, and MEK not being involved).
An increase in NGF mRNA has been detected in the hippocampus, but not cortex, of mice given 5% of the diet as yamabushitake for a period of seven days to around 1.3-fold of control.
Yamabushitake ethanolic extract appears to increase NGF mRNA levels, and this has been confirmed following oral administration to mice
Secretion of NGF from astrocytes has been noted to be increased with 150ug/mL of the ethanolic extract but not 50-100ug/mL while isolated erinacines (A-C) are known to stimulate NGF secretion at 1mM concentrations, with a potency greatly exceeding that of adrenaline at the same concentrations.
Seceretion of NGF from astrocytes has been noted to be increased with incubation of yamabushitake ethanolic extract
When looking at neurons specifically, yamabushitake appears to promote neuronal prolongation and formation of myelin
Neuronal excitability from glutamic acid appears to be attenuated in the presence of yamabushitake extracts,
An analogue of the Hericenones, called 3-hydroxyhericenone, has been implicated in preserving neurons from death induced by endoplasmic reticulum stress. This mechanism of action is also seen with various benzene compounds in Yamabushitake.
It has also been shown, in vitro, to enhance myelination (production of myelin sheath) of neurons, which may be downstream of NGF.
Yamabushitake appears to protect rats against cognitive decline caused by β-amyloid pigmentation at the same 5% of the diet seen previously.
One human study using 3g of 98% Yamabushitake powder (in capsule form) showed significantly improvements on a rating scale of dementia in persons suffering from general cognitive decline. The supplement increased cognition relative to control, and the degree of improvement increased with time; however, 4 weeks after cessation saw the start of a decline back to normal despite still being significantly elevated above control.
Anxiety and Depressive symptoms have also been reduced in humans fed 2g of Yamabushitake, via cookies, over the course of 4 weeks. There was a significant difference between groups on the measurements of concentration and irritability, favoring the Yamabushitake group.
In one study conducted in rats, Yamabushitake water extract was able to promote neuronal regrowth after crushing injury. Rats that had a gluteal nerve damaged (purposefully) during surgery were able to walk better after ingestion of water containing the extract of the fruits. Two doses used in this study were 10 or 20mL per kg bodyweight daily, but the exact mg or mmol dose was not recorded; the two doses, however, did not differ between each other. This was conducted as a follow-up to an in vitro study suggesting neuronal growth from Yamabushitake, which showed no toxic symptoms.
Hericenone B has been shown to exert anti-platelet actions by inhibiting signalling from collagen through α2/β1 to release arachidonic acid (one of the two receptors that mediates thrombosis via collagen); the mechanism appears to be potent but specific in tested rabbits, with complete inhibition at 30μM (similar to 5μM aspirin as reference drug) and near complete at 10μM. Interestingly, hericenones C-E failed to have any influence on collagen-induced platelet aggregation, and while hericenone B was active on other forms of aggregation (adrenaline and U46619 but not ADP nor thrombin) it was less effective.
Hericenone B appears to potently and specifically inhibit collagen-induced platelet aggregation, with other hericenones not having much of an effect and other forms of aggregation not being significantly affected. The concentration this occurs at suggests that it is biologically relevant
Yamabushitake appears to be an ACE inhibitor (hot water extract of the fruiting bodies) with an IC50 value of 580+/-23µg/mL, significantly less than the most potent tested mushroom Ganoderma lucidum (50µg/mL).
Hot water extracts of mushrooms tends to be more potent ACE inhibitors than ethanolic or methanolic extracts, and mushroom bioactives that have been noted to inhibit ACE include D-mannose (IC50 of 3mg/mL) and L-pipecolic acid (IC50 of 23.7mg/mL). As these molecules themselves are weaker than yamabushitake, it is currently thought that bioactives peptides underlie the ACE inhibitor potential as they have been detected in mushrooms before (Val-Ile-Glu-Lys-Tyr-Pro and Gly-Glu-Pro)
Yamabushitake has ACE inhibiting properties, although they appear to be pretty weak and may not be biologically relevant. The exact molecule underlying these effects is not currently known, but it may be a bioactive peptide
Both a hot water and ethanolic extract of yamabushitake have been tested in hyperlipidemic mice at 2% of the diet (1.896-3.16g/kg hot water and 2.016-3.36g/kg ethanolic) is able to reduce triglycerides (8% hot water and 27.1% ethanolic relative to control) without any apparent effect on HDL-C nor total cholesterol. These hypolipidemic effects were also observed in liver tissue (29.8% hot water and 38.8% ethanolic) and was thought to be related to the ability of the ethanolic extract to act as a PPARα agonist with an EC50 value of 40µg/mL; there was an increase in genes downstream of PPARα but no changes in PPARα expression.
Yamabushitake may act as a PPARα agonist and reduce triglycerides without any apparent effect on cholesterol
Although both the hot water and ethanolic extracts have been found inactive on cholesterol and HDL-C, an extract derived from the mycelium of yamabushitake (ethanolic extract which was then lyophilized) appeared to reduce LDL by 45.5% and improve HDL-C by 31.1% when taken at an oral dose of 200mg/kg with 50mg/kg also being somewhat active.
Although the fruiting body of the mushroom (edible portion) does not appear to significantly influence lipoprotein and cholesterol metabolism, the mycelium may reduce cholesterol
Supplementation of both the hot water and ethanolic extracts of yamabushitake to mice (1.896-3.16g/kg hot water and 2.016-3.36g/kg ethanolic) has been found to increase the expression of several genes involved in fat metabolism including Acad1, Srebf1, and Slc27a1, which were thought to be due to activating PPARα.
Yamabushitake appears to be a PPARα agonist, which may contribute to fat burning properties
Supplementation of yamabushitake (1.896-3.16g/kg hot water extract or 2.016-3.36g/kg of the ethanolic extract) to mice is able to attenuate weight gain during a high fat diet by 30% (hot water) and 42.4% (ethanolic) associated with less fat accumulation in the liver and mesenteric adipose tissue.
The mycelium extract at 50-200mg/kg in rats, despite having cholesterol reducing properties, has failed to significantly influence body weight over the course of four weeks.
Yamabushitake has been noted to suppress LPS-induced macrophage activation (mostly chloroform fraction, but also seen with water and alcoholic extracts) associated with less activation of c-Jun N-terminal kinase and less nuclear translocation of NF-kB.
The polysaccharide known as HEF-AP Fr II (a beta-glucan), conversely, has been found to stimulate macrophage activity itself as assessed by TNF-α and IL-β release at a concentration of 1mg/mL. This may be related to the increase in macrophage and T-cell count seen with incubations of this mushroom.
Differing compounds in yamabushitake appear to differently modulate the immune system, with the polysaccharides appearing to be immunostimulatory but other molecules (mostly in the chloroform extract) appearing to suppress macrophage activation
A study in topically wounded rats with the water extract of yamabushitake has noted that immune cell accumulation in the wound was reduced in the yamabushitake group relative to control.
Some suppression of chemotaxis may occur in wounds
In vitro, the hot water and ethanolic extracts of yamabushitake show anti-metastatic potential in CT-26 colon cancer cells at 500µg/mL associated with less ERK and JNK phosphorylation which resulted in less MMP secretion and lamellipodia formation.
Both the hot water and ethanolic extracts of yamabushitake appear to inhibit metastasis of colon cancer cells to the lung by 66-69% with 10mg/kg injections of extracts made of the fruiting bodies.
Yamabushitake is associated with increasing the rate of repair of flesh wounds when the water extract is applied to the wound.
Toxicology studies in rats suggest that doses up to 5g/kg bodyweight are safe in rats when given as MUNOPHIL, which is a combination of Yamabushitake and Panax Ginseng. The percentage of this compound by weight that is Yamabushitake was not listed.
There has been one case study of a 63 year old man who suffered acute respiratory failure, and the excess lymphocytes in his lungs showed high reactivity to Yamabushitake daily for 4 months in dosages commonly bought. The connection between the two, when rated, is seen as a 'probably' connection.